The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial.

@article{Albrecht1995ThePB,
  title={The pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in a phase I trial.},
  author={Clemens F. Albrecht and P. B. Kruger and Berend J. Smit and Mandy Freestone and L Gouws and Rhonda Miller and Petronette van Jaarsveld},
  journal={South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde},
  year={1995},
  volume={85 9},
  pages={861-5}
}
OBJECTIVE To study the pharmacokinetic behaviour of hypoxoside taken orally by 24 patients with lung cancer. DESIGN Randomised open study with three single doses of 1,600, 2,400 and 3,200 mg standardised Hypoxis plant extract (200 mg capsules) and a multiple-dose study on the first 6 patients taking 4 capsules 3 times daily for 11 days. PARTICIPANTS AND SETTING Patients with histologically proven squamous, large-cell or adenocarcinoma were hospitalised at the Radiation Oncology Ward, Karl… CONTINUE READING